Table 1.
Demographic and clinical variables in patients with nonischemic cardiomyopathy
| Variable (n = 19) |
Frequency (Proportion) | Variable (n = 19) |
Frequency (Proportion) |
|---|---|---|---|
| Age, years | 61.8±11.2 | Diabetes | 4 (21.1%) |
| Men | 11 (57.9%) | Hypertension | 5 (26.3%) |
| Chest pain | 2 (10.5%) | Mean EDD (mm) | 48±14 |
| Dyspnoea | 13 (68.4%) | Mean ESD (mm) | 32±9 |
| Syncope | 4 (21.1%) | Mean LVEF, % | 37.4±12.7 |
| Duration of symptoms, months | 13.1±12.4 | LVEF <35% | 8 (42.1%) |
| NYHA I | 4 (21.1%) | Hb, g/L | 143.9±13.4 |
| NYHA II | 12 (63.2%) | Creatinine, μmol/L | 85.5±20.9 |
| NYHA III | 3 (15.8%) | eGFR, ml/min/m [2] | 74.8±13.6 |
| History of AF | 3 (15.8%) | ICD | 10 (52.6%) |
| History of VT | 11 (57.9%) | CRTd | 5 (26.3%) |
| Inducible VT | 16 (84%) | Beta blockers | 16 (84.2%) |
| VT ablation | 16 (84%) | ARNi/ACEi/ARB | 13 (68.4%) |
| Serum BNP (pg/ml) | 158±126 | Spironolactone | 6 (31.6%) |
| QRS>120 ms (LBBB) | 5 (26.3%) | Amiodarone/Mexiletene | 4 (21%)/ 2 (11%) |
| QRS≤120 ms | 14 (74%) | Failed antiarrhythmic drugs | 6 (32%) |
Abbreviations: SD, standard deviation; Hb, haemoglobin; eGFR, estimated glomerular filtration rate; AF, atrial fibrillation; VT, ventricular tachycardia; BNP, brain natriuretic peptide; LBBB, left bundle branch block; EDD, end-diastolic diameter; ESD, end-systolic diameter; LVEF, LV ejection fraction; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; ICD, implantable cardiac defibrillators; CRTd, cardiac resynchronization therapy device; ARNi, angiotensin receptor and neprilysin inhibitor; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker